Shri Swami Samarth Pharmaceuticals Limited - Company Profile

It is a pharma public limited company based in Aurangabad, Maharashtra, India, established in 2004.
2004 Aurangabad, Maharashtra, India Active
Last Updated:
Access Report
About Shri Swami Samarth Pharmaceuticals Limited

Shri Swami Samarth Pharmaceuticals Limited, a active public limited company, was established on 08 October 2004 in Aurangabad, Maharashtra, India. Engaging in drug formulation & development within the trade sector, it holds CIN: U24230MH2004PLC149048. Registered under ROC Roc Mumbai Ii. it is unlisted. It has an authorized capital of ₹1.50 M and a paid-up capital of ₹0.50 M.

It upholds a compliant status. Employing 17 professional, Its leadership includes Tejaswini Shahadev Patil (Director), Vaishali Patil Shahadev (Director), Shahadev Ganpatrao Patil (Director). Past directors included Shrikant Nanabhau Khangar, Shashikala Vishwanath Patil, Ramesh Narayan Choudhari. It holds ₹1.67 M open charges and no settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at C-24, Chikalthana,, Aurangabad, Maharashtra, 431006.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24230MH2004PLC149048

  • Registration Number

    149048

  • Incorporation Date

    08 October 2004

  • Authorized Capital

    ₹1.50 M

  • Paid-Up Capital

    ₹0.50 M

  • ROC Code

    Roc Mumbai Ii

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 1.50 M
  • Paid Up Capital ₹ 0.50 M
  • Company Age 21 Year, 4 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 1.67 M
  • Revenue Growth **** 7.48%
  • Profit Growth **** -68.79%
  • Ebitda **** -164.50%
  • Net Worth 9.62%
  • Total Assets -19.37%
Company report

Shri Swami Samarth Pharmaceuticals Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Shri Swami Samarth Pharmaceuticals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Shri Swami Samarth Pharmaceuticals Limited?
Current Directors
Name Designation Appointment Date Status
Tejaswini Shahadev Patil Director 05 Apr 2022 Current
Vaishali Patil Shahadev Director 05 Apr 2022 Current
Shahadev Ganpatrao Patil Director 05 Apr 2022 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Additional Director 30 Sep 2013 Past
Pramod Abcsdd Director 01 Nov 2013 Past
Pramod Abcsdd Director 01 Oct 2013 Past
Pramod Abcsdd Additional Director 30 Sep 2022 Past
Pramod Abcsdd Director 01 Oct 2013 Past
Pramod Abcsdd Director 01 Jan 2013 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Shri Swami Samarth Pharmaceuticals.

Shri Swami Samarth Pharmaceuticals Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.48% increase. The company also saw a substantial fall in profitability, with a 68.79% decrease in profit. The company's net worth moved up by a moderate rise of 9.62%.

Shri Swami Samarth Pharmaceuticals revenue growth over time
Shri Swami Samarth Pharmaceuticals profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 7.48%
*******
*******
*******
*******
Revenue from Operations
*******
 -2.23%
*******
*******
*******
*******
Total Assets
*******
 -19.37%
*******
*******
*******
*******
Profit or Loss
*******
 -68.79%
*******
*******
*******
*******
Net Worth
*******
 9.62%
*******
*******
*******
*******
EBITDA
*******
 -164.50%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Shri Swami Samarth Pharmaceuticals?

In 2023, Shri Swami Samarth Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹1,671,426.00

Satisfied Charges

₹0

Charges Breakdown by Lending Institutions
  • State Bank Of Hyerabad : 0.09 Cr
  • Hdfc Bank Limited : 0.08 Cr
Latest Charge Details
Date Lender Amount Status
31 Jul 2023 Hdfc Bank Limited ₹0.77 M Open
21 Mar 2005 State Bank Of Hyerabad ₹0.90 M Open

Explore comprehensive loan charge details -

How Many Employees Work at Shri Swami Samarth Pharmaceuticals?

Shri Swami Samarth Pharmaceuticals has a workforce of 17 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Shri Swami Samarth Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shri Swami Samarth Pharmaceuticals's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Shri Swami Samarth Pharmaceuticals
Recent Activity within the Organization
  • Annual General Meeting

    Progress on Shri Swami Samarth Pharmaceuticals Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was documented.

  • Balance Sheet

    The activity Shri Swami Samarth Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai Ii. was completed.

  • Charges

    A charge with Hdfc Bank Limited amounted to Rs. 0.77 M with Charge ID 100812823 was registered on 31 Jul 2023. was recorded as a recent event.

  • Director Appointment

    The activity Tejaswini Shahadev Patil was appointed as a Director was appointed as a Director on 05 Apr 2022 & has been associated with this company since 3 years 10 months . was completed.

  • Director Appointment

    Progress on Vaishali Patil Shahadev was appointed as a Director was appointed as a Director on 05 Apr 2022 & has been associated with this company since 3 years 10 months . was documented.

  • Director Appointment

    Shahadev Ganpatrao Patil was appointed as a Director was appointed as a Director on 05 Apr 2022 & has been associated with this company since 3 years 10 months . was recorded as a recent event.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Shri Swami Samarth Pharmaceuticals Limited?

The CIN of Shri Swami Samarth Pharmaceuticals Limited is U24230MH2004PLC149048.

Where is Shri Swami Samarth Pharmaceuticals Limited headquartered?

Shri Swami Samarth Pharmaceuticals Limited is headquartered at C-24, Chikalthana,, Aurangabad, Maharashtra, 431006.

When was Shri Swami Samarth Pharmaceuticals Limited incorporated?

Shri Swami Samarth Pharmaceuticals Limited was incorporated on 08 October 2004.

Who are the current directors of Shri Swami Samarth Pharmaceuticals Limited?

The current directors of Shri Swami Samarth Pharmaceuticals Limited are

What is the primary industry of Shri Swami Samarth Pharmaceuticals Limited?

The primary industry of Shri Swami Samarth Pharmaceuticals Limited is Trade.

Is Shri Swami Samarth Pharmaceuticals Limited a listed company?

Shri Swami Samarth Pharmaceuticals Limited is unlisted.

What is the capital structure of Shri Swami Samarth Pharmaceuticals Limited?

The authorized capital of Shri Swami Samarth Pharmaceuticals Limited is ₹1.50 M, and the paid-up capital is ₹0.50 M.

What is the compliance status of Shri Swami Samarth Pharmaceuticals Limited?

The compliance status of Shri Swami Samarth Pharmaceuticals Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available